Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 382

1.

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK.

JAMA Oncol. 2018 Sep 6. doi: 10.1001/jamaoncol.2018.3691. [Epub ahead of print]

PMID:
30193295
2.

The prognostic effects of somatic mutations in ER-positive breast cancer.

Griffith OL, Spies NC, Anurag M, Griffith M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, Hundal J, Ainscough BJ, Skidmore ZL, Campbell K, Kumar R, Fronick C, Cook L, Snider JE, Davies S, Kavuri SM, Chang EC, Magrini V, Larson DE, Fulton RS, Liu S, Leung S, Voduc D, Bose R, Dowsett M, Wilson RK, Nielsen TO, Mardis ER, Ellis MJ.

Nat Commun. 2018 Sep 4;9(1):3476. doi: 10.1038/s41467-018-05914-x.

3.

gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data.

Saltzman AB, Leng M, Bhatt B, Singh P, Chan DW, Dobrolecki LE, Chandrasekaran H, Choi JM, Jain A, Jung SY, Lewis MT, Ellis MJ, Malovannaya A.

Mol Cell Proteomics. 2018 Aug 9. pii: mcp.TIR118.000850. doi: 10.1074/mcp.TIR118.000850. [Epub ahead of print]

4.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ.

Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.

5.

Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.

Reinert T, de Paula B, Shafaee MN, Souza PH, Ellis MJ, Bines J.

Chin Clin Oncol. 2018 Jun;7(3):25. doi: 10.21037/cco.2018.06.06.

6.

Cervical Spine Dysfunction Following Pediatric Sports-Related Head Trauma.

Ellis MJ, McDonald PJ, Olson A, Koenig J, Russell K.

J Head Trauma Rehabil. 2018 Jul 24. doi: 10.1097/HTR.0000000000000411. [Epub ahead of print]

PMID:
30045221
7.

Cancer incidence and mortality rates and trends in Trinidad and Tobago.

Warner WA, Lee TY, Badal K, Williams TM, Bajracharya S, Sundaram V, Bascombe NA, Maharaj R, Lamont-Greene M, Roach A, Bondy M, Ellis MJ, Rebbeck TR, Slovacek S, Luo J, Toriola AT, Llanos AAM.

BMC Cancer. 2018 Jul 4;18(1):712. doi: 10.1186/s12885-018-4625-x.

8.

Evaluation of a Medically Supervised Concussion Protocol for Youth Hockey in Canada.

Ellis MJ, Leiter J, Cordingley DM, Reimer K, Koenig J, Russell KF.

Can J Neurol Sci. 2018 Jul;45(4):424-431. doi: 10.1017/cjn.2018.30. Epub 2018 Jul 3.

PMID:
29969083
9.

The prognostic significance of chronotropic incompetence in patients with severe left ventricular systolic function referred for cardiac transplant assessment.

Patel HC, Yo S, Nanayakkara S, Selkrig L, Ellis MJ, Naughton MT, Kaye DM, Mariani JA.

Eur J Prev Cardiol. 2018 Jan 1:2047487318783880. doi: 10.1177/2047487318783880. [Epub ahead of print] No abstract available.

PMID:
29916724
10.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

PMID:
29860917
11.

FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation.

Nguyen TM, Kabotyanski EB, Dou Y, Reineke LC, Zhang P, Zhang XH, Malovannaya A, Jung SY, Mo Q, Roarty KP, Chen Y, Zhang B, Neilson JR, Lloyd RE, Perou CM, Ellis MJ, Rosen JM.

Cancer Res. 2018 Aug 1;78(15):4229-4240. doi: 10.1158/0008-5472.CAN-18-0631. Epub 2018 May 29.

PMID:
29844125
12.

Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.

Anurag M, Punturi N, Hoog J, Bainbridge MN, Ellis MJ, Haricharan S.

Clin Cancer Res. 2018 May 23. doi: 10.1158/1078-0432.CCR-17-3702. [Epub ahead of print]

PMID:
29793947
13.

Fulvestrant in management of hormone receptor-positive metastatic breast cancer.

Shafaee MN, Ellis MJ.

Future Oncol. 2018 Aug;14(18):1789-1800. doi: 10.2217/fon-2017-0489. Epub 2018 May 22.

PMID:
29783894
14.

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.

Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, Hamilton RA, Yu Y, Lonard DM, Wang J, Wang SP, Edwards DG, Lavere PF, Shao J, Yi P, Jain A, Jung SY, Malovannaya A, Li S, Shao J, Roeder RG, Ellis MJ, Qin J, Fuqua SAW, O'Malley BW, Foulds CE.

Oncogene. 2018 May 11. doi: 10.1038/s41388-018-0284-2. [Epub ahead of print]

15.

Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.

Reinert T, Gonçalves R, Ellis MJ.

Curr Treat Options Oncol. 2018 Apr 16;19(5):23. doi: 10.1007/s11864-018-0538-9. Review.

PMID:
29663173
16.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

PMID:
29578538
17.

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.

Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J, Thirlwell J, Fazal M, Ellis MJ.

Eur J Cancer. 2018 May;94:206-215. doi: 10.1016/j.ejca.2018.02.026. Epub 2018 Mar 22.

18.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Sep 1;110(9):1003-1008. doi: 10.1093/jnci/djy017.

PMID:
29554282
19.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

PMID:
29472518
20.

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.

Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, Houtman R, Wang G.

Oncotarget. 2018 Jan 8;9(6):6924-6937. doi: 10.18632/oncotarget.24023. eCollection 2018 Jan 23.

21.

Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).

Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z.

Breast Cancer. 2018 May;25(3):356-364. doi: 10.1007/s12282-018-0838-8. Epub 2018 Feb 15.

PMID:
29450827
22.

Patient-Specific Alterations in CO2 Cerebrovascular Responsiveness in Acute and Sub-Acute Sports-Related Concussion.

Mutch WAC, Ellis MJ, Ryner LN, McDonald PJ, Morissette MP, Pries P, Essig M, Mikulis DJ, Duffin J, Fisher JA.

Front Neurol. 2018 Jan 24;9:23. doi: 10.3389/fneur.2018.00023. eCollection 2018.

23.

Management and Return to Play Considerations in an Elite Hockey Player with Temporal Lobe Epilepsy.

Ellis MJ, Ritchie L, Essig M, Ng M, Tamayo A, Serletis D.

Curr Sports Med Rep. 2018 Jan;17(1):10-12. doi: 10.1249/JSR.0000000000000439. No abstract available.

PMID:
29315101
24.

Management of an Adolescent Athlete with Sports-Related Concussion and Intraparenchymal Hemorrhage.

Ellis MJ, Barnes J, Cordingley DM, Bunge M, McDonald PJ, Ritchie L.

Curr Sports Med Rep. 2018 Jan;17(1):7-9. doi: 10.1249/JSR.0000000000000438. No abstract available.

PMID:
29315100
25.

Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.

Pillai SG, Li S, Siddappa CM, Ellis MJ, Watson MA, Aft R.

Breast Cancer Res. 2018 Jan 2;20(1):2. doi: 10.1186/s13058-017-0927-1.

26.

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N.

Cancer Res. 2018 Jan 15;78(2):489-500. doi: 10.1158/0008-5472.CAN-16-1911. Epub 2017 Nov 28. Erratum in: Cancer Res. 2018 Jun 15;78(12):3403.

PMID:
29183891
27.

Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.

Zhou JY, Chen L, Zhang B, Tian Y, Liu T, Thomas SN, Chen L, Schnaubelt M, Boja E, Hiltke T, Kinsinger CR, Rodriguez H, Davies SR, Li S, Snider JE, Erdmann-Gilmore P, Tabb DL, Townsend RR, Ellis MJ, Rodland KD, Smith RD, Carr SA, Zhang Z, Chan DW, Zhang H.

J Proteome Res. 2017 Dec 1;16(12):4523-4530. doi: 10.1021/acs.jproteome.7b00362. Epub 2017 Nov 16.

28.

Silent but deadly: IS200 promotes pathogenicity in Salmonella Typhimurium.

Ellis MJ, Carfrae LA, Macnair CR, Trussler RS, Brown ED, Haniford DB.

RNA Biol. 2018 Feb 1;15(2):176-181. doi: 10.1080/15476286.2017.1403001. Epub 2017 Dec 8.

PMID:
29120256
29.

Reply.

Ellis MJ, Ritchie L, McDonald P, Russell K.

Clin J Sport Med. 2017 Sep 28. doi: 10.1097/JSM.0000000000000490. [Epub ahead of print] No abstract available.

PMID:
28976404
30.

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?

Haricharan S, Ellis MJ.

Oncoscience. 2017 Sep 21;4(7-8):77-78. doi: 10.18632/oncoscience.363. eCollection 2017 Jul. No abstract available.

31.

Chemical genomics reveals mechanistic hypotheses for uncharacterized bioactive molecules in bacteria.

French S, Ellis MJ, Coutts BE, Brown ED.

Curr Opin Microbiol. 2017 Oct;39:42-47. doi: 10.1016/j.mib.2017.09.005. Epub 2017 Sep 26. Review.

PMID:
28957731
32.

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K.

Clin Cancer Res. 2017 Dec 1;23(23):7288-7300. doi: 10.1158/1078-0432.CCR-17-1544. Epub 2017 Sep 25.

33.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

PMID:
28874413
34.

Zirconium amine tris(phenolate): A more effective initiator for biomedical lactide.

Jones MD, Wu X, Chaudhuri J, Davidson MG, Ellis MJ.

Mater Sci Eng C Mater Biol Appl. 2017 Nov 1;80:69-74. doi: 10.1016/j.msec.2017.03.242. Epub 2017 Mar 29.

PMID:
28866217
35.

Graded Aerobic Treadmill Testing in Adolescent Traumatic Brain Injury Patients.

Cordingley DM, Girardin R, Morissette MP, Reimer K, Leiter J, Russell K, Ellis MJ.

Can J Neurol Sci. 2017 Nov;44(6):684-691. doi: 10.1017/cjn.2017.209. Epub 2017 Aug 29.

PMID:
28849757
36.

CDK4/6 inhibition triggers anti-tumour immunity.

Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ.

Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.

37.

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ.

Cancer Discov. 2017 Oct;7(10):1168-1183. doi: 10.1158/2159-8290.CD-16-1179. Epub 2017 Aug 11.

PMID:
28801307
38.

Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner.

Wang X, Mooradian AD, Erdmann-Gilmore P, Zhang Q, Viner R, Davies SR, Huang KL, Bomgarden R, Van Tine BA, Shao J, Ding L, Li S, Ellis MJ, Rogers JC, Townsend RR, Fenyö D, Held JM.

Sci Signal. 2017 Aug 8;10(491). pii: eaam8065. doi: 10.1126/scisignal.aam8065.

39.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

PMID:
28679771
40.

Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.

Ellis MJ.

Breast. 2017 Aug;34 Suppl 1:S104-S107. doi: 10.1016/j.breast.2017.06.039. Epub 2017 Jun 30.

41.

Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE.

Cancer Immunol Res. 2017 Jul;5(7):516-523. doi: 10.1158/2326-6066.CIR-16-0264. Epub 2017 Jun 15.

42.

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.

Goncalves R, DeSchryver K, Ma C, Tao Y, Hoog J, Cheang M, Crouch E, Dahiya N, Sanati S, Barnes M, Sarian LOZ, Olson J, Allred DC, Ellis MJ.

Breast Cancer Res Treat. 2017 Sep;165(2):355-364. doi: 10.1007/s10549-017-4329-y. Epub 2017 Jun 13.

43.

Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.

Goncalves R, Reinert T, Ellis MJ.

J Clin Oncol. 2017 Aug 10;35(23):2718-2719. doi: 10.1200/JCO.2017.73.0424. Epub 2017 Jun 5. No abstract available.

PMID:
28581884
44.

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M, Han L, Elliott CR, Shepherd LE, Goss PE, Ali SM.

Cancer. 2017 Jul 1;123(13):2444-2451. doi: 10.1002/cncr.30682. Epub 2017 May 2.

45.

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.

Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER.

Ann Oncol. 2017 May 1;28(5):1070-1077. doi: 10.1093/annonc/mdx048.

46.

Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Townsend RR, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Apr 25;8:15479. doi: 10.1038/ncomms15479. No abstract available.

47.

Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps.

Shafaee MN, Ellis MJ.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw307. No abstract available.

PMID:
28376181
48.

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Mar 28;8:14864. doi: 10.1038/ncomms14864.

49.

A transposon-derived small RNA regulates gene expression in Salmonella Typhimurium.

Ellis MJ, Trussler RS, Charles O, Haniford DB.

Nucleic Acids Res. 2017 May 19;45(9):5470-5486. doi: 10.1093/nar/gkx094.

50.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

Supplemental Content

Loading ...
Support Center